dm+d

Unassigned

New Medicines

Moderate to severe chronic obstructive pulmonary disease (COPD)

Information

New molecular entity
Sanofi
Regeneron

Development and Regulatory status

None
Phase II Clinical Trials
Phase III Clinical Trials

Category

Anti-IL-33 monoclonal antibody, administered two- or four-weekly.
An estimated 1.2 million people are affected by COPD in the UK. There are 115,000 new diagnoses a year. Nevertheless, COPD remains underdiagnosed. 60-85% of patients, mainly with mild-to-moderate disease, are thought to remain undiagnosed [1].
Moderate to severe chronic obstructive pulmonary disease (COPD)
Subcutaneous injection